{"nctId":"NCT04119843","briefTitle":"Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function","startDateStruct":{"date":"2020-02-19","type":"ACTUAL"},"conditions":["Known or Suspected Focal Liver Lesions","Severe Renal Impairment"],"count":87,"armGroups":[{"label":"Mangoral","type":"EXPERIMENTAL","interventionNames":["Drug: Mangoral"]}],"interventions":[{"name":"Mangoral","otherNames":["Orviglance","CMC-001","ACE-MBCA"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female participants 18 years and older.\n* Known or suspected focal liver lesions based on medical history and previous laboratory and/or imaging examinations.\n* Severe renal impairment (estimated glomerular filtration rate \\[eGFR\\] \\< 30 mL/min/1.73 m\\^2) based on medical history and previous laboratory examinations, at least once, within the last 3 months prior to the Baseline Visit, or participants with an increase in serum creatinine ≥ 0.3 mg/dL within 48 hours or ≥ 50% within 7 days prior to the Baseline Visit.\n\nExclusion Criteria:\n\n* Participants with simple liver cysts only.\n* Any investigational drug or device within 6 weeks prior to the Baseline Visit.\n* Any magnetic resonance imaging (MRI) contrast media within 6 weeks prior to Baseline Visit or scheduled to receive any contrast medium before the last study visit.\n* Participants with severe hepatic impairment (according to Child-Pugh score C).\n* Participants scheduled for surgery before last study visit.\n* Participants with encephalopathy / neurodegenerative or acute neurological disorders.\n* Participants with hemochromatosis.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Co-primary Endpoint: Lesion Border Delineation in Combined MRI Compared to Unenhanced MRI","description":"Visualization of focal liver lesions was measured by 2 co-primary variables: 'lesion border delineation' and 'lesion contrast' compared to liver background. Qualitative assessment determined on the 4-point scales for up to 15 lesions per participant. Each lesion was assessed for lesion border delineation from 1 (poor: lesion border is poorly distinct) to 4 (excellent: lesion border is sharply and clearly distinct). Central reading sessions were undertaken by 3 independent, blinded readers.\n\nThe scores were calculated for each participant by summing the individual lesion scores and calculating the mean. The total score could range from 1 to 4 for each participant with higher scores representing a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.51","spread":"0.815"},{"groupId":"OG001","value":"3.46","spread":"0.861"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.00","spread":"0.952"},{"groupId":"OG001","value":"3.80","spread":"0.607"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.31","spread":"0.847"},{"groupId":"OG001","value":"2.97","spread":"0.782"}]}]}]},{"type":"PRIMARY","title":"Co-primary Endpoint: Lesion Contrast in Combined MRI Compared to Unenhanced MRI","description":"Visualization of focal liver lesions was measured by 2 co-primary variables: 'lesion border delineation' and 'lesion contrast' compared to liver background. Qualitative assessment determined on the 4-point scales for up to 15 lesions per participant. Each lesion was assessed for lesion contrast from 1 (poor: difference in signal intensity between the lesion and the surrounding normal liver tissue is poor) to 4 (excellent: difference in signal intensity between the lesion and the surrounding liver is marked). Central reading sessions were undertaken by 3 independent, blinded readers.\n\nThe scores were calculated for each participant by summing the individual lesion scores and calculating the mean. The total score could range from 1 to 4 for each participant with higher scores representing a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.49","spread":"0.813"},{"groupId":"OG001","value":"3.47","spread":"0.844"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.84","spread":"0.926"},{"groupId":"OG001","value":"3.86","spread":"0.417"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.51","spread":"0.919"},{"groupId":"OG001","value":"3.33","spread":"0.684"}]}]}]},{"type":"SECONDARY","title":"Number of Lesions Detected by Each MRI Method","description":"Assessments of unenhanced MRI, mangoral-enhanced MRI, and combined MRI for detection of lesions were undertaken by on-site readers (assessing participants at their own site) and during central reading sessions by 3 independent, blinded readers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"9.07"},{"groupId":"OG001","value":"6.2","spread":"9.35"},{"groupId":"OG002","value":"6.4","spread":"9.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"5.18"},{"groupId":"OG001","value":"4.3","spread":"5.39"},{"groupId":"OG002","value":"4.2","spread":"5.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"5.07"},{"groupId":"OG001","value":"3.6","spread":"5.34"},{"groupId":"OG002","value":"3.2","spread":"4.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"5.58"},{"groupId":"OG001","value":"4.5","spread":"5.55"},{"groupId":"OG002","value":"4.3","spread":"5.59"}]}]}]},{"type":"SECONDARY","title":"Lesion Border Delineation in Mangoral-enhanced MRI Compared to Unenhanced MRI","description":"Visualization of focal liver lesions was measured by variables: 'lesion border delineation' and 'lesion contrast' compared to liver background. Qualitative assessment determined on the 4-point scales for up to 15 lesions per participant. Each lesion was assessed for lesion border delineation from 1 (poor: lesion border is poorly distinct) to 4 (excellent: lesion border is sharply and clearly distinct). Central reading sessions were undertaken by 3 independent, blinded readers.\n\nThe scores were calculated for each participant by summing the individual lesion scores and calculating the mean. The total score could range from 1 to 4 for each participant with higher scores representing a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","spread":"0.783"},{"groupId":"OG001","value":"3.34","spread":"0.814"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.95","spread":"0.986"},{"groupId":"OG001","value":"3.71","spread":"0.647"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":"0.854"},{"groupId":"OG001","value":"2.86","spread":"0.881"}]}]}]},{"type":"SECONDARY","title":"Lesion Contrast in Mangoral-enhanced MRI Compared to Unenhanced MRI","description":"Visualization of focal liver lesions was measured by variables: 'lesion border delineation' and 'lesion contrast' compared to liver background. Qualitative assessment determined on the 4-point scales for up to 15 lesions per participant. Each lesion was assessed for lesion contrast from 1 (poor: difference in signal intensity between the lesion and the surrounding normal liver tissue is poor) to 4 (excellent: difference in signal intensity between the lesion and the surrounding liver is marked). Central reading sessions were undertaken by 3 independent, blinded readers.\n\nThe scores were calculated for each participant by summing the individual lesion scores and calculating the mean. The total score could range from 1 to 4 for each participant with higher scores representing a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","spread":"0.787"},{"groupId":"OG001","value":"3.52","spread":"0.735"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.80","spread":"0.940"},{"groupId":"OG001","value":"3.53","spread":"0.816"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.46","spread":"0.933"},{"groupId":"OG001","value":"3.18","spread":"0.882"}]}]}]},{"type":"SECONDARY","title":"Confidence in Lesion Detection Score","description":"Each lesion was evaluated on a 3-point scale: 1 (lesion is detected with low confidence), 2 (lesion is detected with moderate confidence), 3 (lesion is detected with high confidence). Higher confidence in lesion detection scores represent better outcomes.\n\nAssessments of unenhanced MRI, mangoral-enhanced MRI, and combined MRI for confidence in lesion detection were undertaken by on-site readers (assessing participants are their own site) and during central reading sessions by 3 independent, blinded readers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"0.66"},{"groupId":"OG001","value":"2.8","spread":"0.42"},{"groupId":"OG002","value":"2.8","spread":"0.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"0.54"},{"groupId":"OG001","value":"2.8","spread":"0.53"},{"groupId":"OG002","value":"2.8","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"0.26"},{"groupId":"OG001","value":"3.0","spread":"0.20"},{"groupId":"OG002","value":"2.9","spread":"0.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"0.59"},{"groupId":"OG001","value":"2.9","spread":"0.45"},{"groupId":"OG002","value":"2.9","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Confidence in Lesion Localization Score","description":"Each lesion was evaluated on a 3-point scale: 1 (lesion is localized to a liver segment with low confidence), 2 (lesion is localized to a liver segment with moderate confidence), 3 (lesion is localized to a liver segment with high confidence).\n\nAssessments of unenhanced MRI, mangoral-enhanced MRI, and combined MRI for confidence in lesion localization were undertaken by on-site readers (assessing participants at their own site) and during central reading sessions by 3 independent, blinded readers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"0.65"},{"groupId":"OG001","value":"2.9","spread":"0.42"},{"groupId":"OG002","value":"2.8","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"0.57"},{"groupId":"OG001","value":"2.8","spread":"0.51"},{"groupId":"OG002","value":"2.8","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"0.30"},{"groupId":"OG001","value":"3.0","spread":"0.20"},{"groupId":"OG002","value":"3.0","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"0.33"},{"groupId":"OG001","value":"2.9","spread":"0.26"},{"groupId":"OG002","value":"3.0","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Longest Diameter of Largest and Smallest Lesion","description":"Assessments of unenhanced MRI and mangoral-enhanced MRI for lesion dimensions were undertaken during central reading sessions by 3 independent, blinded readers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":"23.75"},{"groupId":"OG001","value":"21.4","spread":"24.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":"25.50"},{"groupId":"OG001","value":"25.3","spread":"26.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":"23.89"},{"groupId":"OG001","value":"17.0","spread":"23.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.2","spread":"32.49"},{"groupId":"OG001","value":"38.2","spread":"29.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.5","spread":"31.49"},{"groupId":"OG001","value":"47.9","spread":"36.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":"31.25"},{"groupId":"OG001","value":"35.2","spread":"27.45"}]}]}]},{"type":"SECONDARY","title":"Percentage Liver Signal Intensity (SI) Enhancement in Mangoral-enhanced MRI Compared to Unenhanced MRI","description":"Quantitative SI was measured by positioning circular regions of interest in a homogenous area in the liver and the assessed liver lesion on the same image. SI liver was defined as the SI of the liver. Liver SI enhancement (%) = (\\[SI liver post contrast - SI liver pre contrast\\] / \\[SI liver pre contrast\\]) × 100.\n\nAssessments of unenhanced MRI and mangoral-enhanced MRI for liver SI were undertaken during central reading sessions by the 3 independent, blinded readers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.159","spread":"148.2818"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.633","spread":"113.7548"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.456","spread":"105.3634"}]}]}]},{"type":"SECONDARY","title":"Liver-to-lesion Contrast (LLC) in Mangoral-enhanced MRI Compared to Unenhanced MRI","description":"Quantitative SI was measured by positioning circular regions of interest in a homogenous area in the liver and the assessed liver lesion on the same image. Up to 5 lesions per participant of ≥ 2 cm in diameter were evaluated and these lesions were the same on pre-and post-contrast images. SI lesion was defined as the SI of these lesions. SI liver was defined as the SI of the liver. LLC = (SI liver - SI lesion) / (SI liver + SI lesion). Higher ratio scores represent a better outcome.\n\nAssessments of unenhanced MRI and mangoral-enhanced MRI for LLC ratio were undertaken during central reading sessions by the 3 independent, blinded readers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.143","spread":"0.1694"},{"groupId":"OG001","value":"0.306","spread":"0.1816"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.109","spread":"0.2739"},{"groupId":"OG001","value":"0.291","spread":"0.2709"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.142","spread":"0.1882"},{"groupId":"OG001","value":"0.331","spread":"0.2162"}]}]}]},{"type":"SECONDARY","title":"Signal-to-noise Ratio (SNR) in Mangoral-enhanced MRI Compared to Unenhanced MRI","description":"Quantitative SI was measured by positioning circular regions of interest in a homogenous area in the liver and the assessed liver lesion on the same image. SI liver was defined as the SI of the liver. Standard deviation of the background noise was measured using the largest possible rectangular region of interest vertical to the patient's abdomen in the direction of the phase-encoding gradient. SNR = SI liver / standard deviation noise. Higher ratio scores represent a better outcome.\n\nAssessments of unenhanced MRI and mangoral-enhanced MRI for SNR were undertaken during central reading sessions by the 3 independent, blinded readers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"286.428","spread":"581.8717"},{"groupId":"OG001","value":"322.951","spread":"365.1663"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"226.367","spread":"362.3748"},{"groupId":"OG001","value":"531.223","spread":"1175.7566"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"248.653","spread":"508.6403"},{"groupId":"OG001","value":"419.706","spread":"694.8662"}]}]}]},{"type":"SECONDARY","title":"Contrast-to-noise Ratio (CNR) in Mangoral-enhanced MRI Compared to Unenhanced MRI","description":"Quantitative SI was measured by positioning circular regions of interest in a homogenous area in the liver and the assessed liver lesion on the same image. Up to 5 lesions per participant of ≥ 2 cm in diameter were evaluated and these lesions were the same on pre-and post-contrast images. SI lesion was defined as the SI of these lesions. SI liver was defined as the SI of the liver. Standard deviation of the background noise was measured using the largest possible rectangular region of interest vertical to the patient's abdomen in the direction of the phase-encoding gradient. CNR = (SI liver - mean of SI lesion) / standard deviation noise. Higher ratio scores represent a better outcome.\n\nAssessments of unenhanced MRI and mangoral-enhanced MRI for CNR were undertaken during central reading sessions by the 3 independent, blinded readers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.564","spread":"197.1474"},{"groupId":"OG001","value":"137.281","spread":"161.1640"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.506","spread":"214.2616"},{"groupId":"OG001","value":"277.270","spread":"650.8484"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.019","spread":"306.2666"},{"groupId":"OG001","value":"241.093","spread":"510.3520"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Change(s) in Recommended Management Based on Diagnostic Performance of Combined MRI or Mangoral-enhanced MRI Compared to Unenhanced MRI","description":"A participant was considered to have a change in recommended management when compared to unenhanced MRI if recommended management was different following assessment of the combined MRI or mangoral-enhanced MRI, including next steps in management (i.e. chemotherapy, surgery, local ablation procedure, combination therapy, or other \\[specify\\]). Recommended patient management from \"other\" in unenhanced MRI to \"other\" in combined MRI or mangoral-enhanced MRI was considered not a change regardless of the free text.\n\nAssessments of unenhanced MRI, mangoral-enhanced MRI, and combined MRI for confidence in lesion detection were undertaken by on-site readers (assessing participants at their own site with access to patient records) and during central reading sessions by 3 independent, blinded readers (without access to patient records).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":87},"commonTop":["Nausea","Diarrhoea","Vomiting","Blood urea increased","Abdominal pain"]}}}